Law ❯ Litigation

Class Action

Securities Fraud Securities Class Action Consumer Rights Investor Rights Legal Representation Securities Law Consumer Protection Securities Litigation Corporate Law Data Privacy

CarMax Securities Class Actions Expand Class Period to Nov. 5 After CEO Ouster

Investors have until Jan. 2 to seek lead‑plaintiff status in litigation over allegedly misleading growth claims.

Dec. 15 Lead-Plaintiff Deadline Set in Baxter Securities Suit Over Novum IQ Pump

Judge Approves Revised Purdue Pharma–Sackler Opioid Settlement

aTyr Securities Suits Intensify as New Filing Expands Class Period Ahead of Dec. 8 Deadline

Avantor Faces Shareholder Class Action Over Competition Disclosures as Lead-Plaintiff Deadline Nears

AT&T Data Breach Settlement: Dec. 18 Claim Deadline for $177 Million Fund

Jasper Therapeutics Investors Face Lead Plaintiff Deadline in Securities Class Action

Synopsys Investors Face Dec. 30 Deadline to Seek Lead Role in Securities Class Action

Molina Investors Face Dec. 2 Deadline To Seek Lead Role In Securities Class Action

Multiple Firms File Securities Class Actions Against Freeport-McMoRan Over Grasberg Safety Claims

Stride Investors Face Jan. 12 Deadline in Securities Class Action Over Enrollment, Compliance Claims

Primo Brands Hit With Securities Class Actions Over Blue Triton Merger Disclosures

Telix Sued by Investors Over Prostate Therapy Claims After SEC Subpoena and FDA Rejection

Inspire Medical Investors Press Class Action Over Inspire V Rollout With Lead-Plaintiff Deadline Jan. 5

Marex Faces Securities Class Action as Firms Urge Investors to Seek Lead Plaintiff by Dec. 8

Amazon Sued in New York Class Action Over Attendance System and Disability Accommodations

Stride Faces Securities Class Action Over Alleged Inflated Enrollments After Sharp Stock Plunge

Firefly Aerospace Faces Securities Class Action Over IPO Disclosures

Multiple Firms File Securities Class Actions Against Telix in Indiana Federal Court Over Prostate Cancer Program Disclosures

MoonLake Investors Face Dec. 15 Deadline in Securities Suits Over Sonelokimab Claims